Daily Medication Pearl: Delafloxacin (Baxdela)

Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.

Medication Pearl of the Day: Delafloxacin (Baxdela)

Indication: Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.

Insight:

  • Dosing: Administer delafloxacin for injection 300 mg by intravenous (IV) infusion over 60 minutes, every 12 hours, or a 450-mg delafloxacin tablet orally every 12 hours for 5 to 14 days total duration.
  • Dosage forms: For Injection 300 mg of delafloxacin (equivalent to 433 mg delafloxacin meglumine) as a lyophilized powder in a single dose vial for reconstitution and further dilution before IV infusion.
  • Adverse events: Most common adverse reactions (incidence ≥ 2%) are nausea, diarrhea, headache, transaminase elevations and vomiting.
  • Mechanism of action: Delafloxacin is an antibacterial drug.
  • Manufacturer: Melinta Therapeutics

Reference

BAXDELA (delafloxacin) Label (fda.gov)